Targeting newly identified ER beta/TGF-beta 1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ER beta selective antagonist in renal cell carcinoma

Song, WB; He, DL; Chen, YL; Yeh, CR; Hsu, IW; Huang, QB; Zhang, X; Chang, LSS; Zuo, L; Chen, JS; Doersch, KM; Chang, CS; Li, L; Yeh, SY

He, DL; Li, L (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Urol, Xian 710061, Shaanxi, Peoples R China.; Yeh, SY (reprint author), Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA.; Yeh, SY (repri

MOLECULAR ONCOLOGY, 2018; 12 (12): 2055

Abstract

Renal cell carcinoma (RCC) has the third highest mortality rate among urological tumors, and 20-30% of RCC patients present with metastatic RCC at the......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索